CD40 and B Chronic Lymphocytic Leukemia Cell Response To Fludarabine: The Influence of NF-kB/Rel Transcription Factors On Chemotherapy-Induced Apoptosis

Leukemia and Lymphoma

Volumn 36, Issue 42067, 2000, Pages 255-262

  Romano, Maria Fiammetta ^a   Lamberti, Annalisa ^a   Turco, Maria Caterina ^a   Venuta, Salvatore ^b  

^a Institute Pascale   (Italy)

^b Italian Federation of Sports Medicine   (Italy)

Author keywords

Apoptosis; CD40; NF KB Rel

Indexed keywords

FLUDARABINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MEMBRANE PROTEIN; OLIGODEOXYNUCLEOTIDE; TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR RECEPTOR; ANTINEOPLASTIC AGENT; CD40 ANTIGEN; DRUG DERIVATIVE; ONCOPROTEIN; VIDARABINE;

APOPTOSIS; ARTICLE; B LYMPHOCYTE; CHRONIC LYMPHATIC LEUKEMIA; HUMAN; PRIORITY JOURNAL; B CELL LEUKEMIA; CELL CULTURE; DRUG ANTAGONISM; IMMUNOLOGY; PATHOLOGY; PHYSIOLOGY; REVIEW;

ANTIGENS, CD40; ANTINEOPLASTIC AGENTS; APOPTOSIS; HUMANS; LEUKEMIA, B-CELL, CHRONIC; NF-KAPPA B; ONCOGENE PROTEINS V-REL; TUMOR CELLS, CULTURED; VIDARABINE;

EID: 0033621706     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428190009148846     Document Type: Article

References (53)

1. Fisher D. E. Apoptosis in cancer therapy: crossing the threshold. Cell 1994; 89: 539 – 42
2. Baldini N. Multidrug resistance - a multiplex phenomenon. Nat Med 1997; 3: 378 – 80
3. Banchereau J., Bazan R., Blanchard D., Briére R., Galizzi J. R., van Kooten C., Liu Y. J., Rousset R., Saekand S. The CD40 antigen and its ligand. Annu Rev Immunol 1994; 12: 881 – 922
4. Smith C. A., Farrah T., Goodwin R. G. The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Cell 1994; 76: 959 – 62
5. Lane P., Traunecker A., Hubele S., Inui S., Lanzavecchia A., Gray D. Activated human T cells express a ligand for the human B cell-associated antigen CD40 which participates in T cell- dependent activation of B lymphocytes. Eur J Immunol 1992; 22: 2573 – 8
6. Roy M., Waldschmidt T., Aruffo A., Ledbetter J. A., Noelle R. J. The regulation of the expression of gp39, the CD40 ligand, on normal and cloned CD4+ T cells. J Immunol 1993; 151: 2497 – 510
7. Foy M. T., Aruffo A., Bajorath J., Buhlmann J. E., Noelle R. J. Immune regulation by CD40 and its ligand gp39. Annu Rev Immunol 1996; 14: 591 – 617
8. Liu Y. J., Johnson G. D., Gordon J., MacLennan I. C. Germinal centres in T-cell-dependent antibody responses. Immunol Today 1992; 13: 17 – 21
9. Durie F. H., Foy T. M., Masters S. R., Laman J. D., Noelle R. J. The role of CD40 in the regulation of humoral and cell- mediated immunity. Immunol Today 1994; 15: 406 – 11
10. Choi M. S., Boise L. H., Gottschalk A. R., Quintas J., Thompson C. B., Klaus G. G. Eur J Immunol 1995; 25: 1352 – 7
11. Baker M. P., Eliopoulos A. G., Young L. S., Armitage R. J., Gregory C. D., Gordon J. Prolonged phenotypic, functional, and molecular change in group I Burkitt lymphoma cells on short- term exposure to CD40 ligand. Blood 1998; 92: 2830 – 43
12. Schattner E. J., Elkon K. B., Yoo D. H., Tumang J., Krammer P. H., Crow M. K., Friedman S. M. CD40 ligation induces Apo-1/Fas expression on human B lymphocytes and facilitates apoptosis through the Apo-1/Fas pathway. J Exp Med 1995; 182: 1557 – 65
13. Funakoshi S., Longo D. L., Beckwith M., Conley D. K., Tsarfaty I., Armitage R. J., Fanslow W. C., Spriggs M. K., Murphy W. J. Inhibition of human B-cell lymphoma growth by CD40 stimulation. Blood 1995; 83: 2787 – 94
14. Dilloo D., Brown M., Roskrow M., Zhong W., Holladay M., Holden W., Brenner M. CD40 ligand induces an antileukemia immune response in vivo. Blood 1997; 92: 1927 – 33
15. Kato K., Cantwell M. J., Sharma S., Kipps T. J. Gene transfer of CD40-ligand induces autologous immune recognition of chronic lymphocytic leukemia B cells. J Clin Invest 1998; 101: 1133 – 41
16. Romano M. F., Lamberti A., Tassone P., Alfinito F., Costantini S., Chiurazzi F., Defrance T., Bonelli P., Tuccillo M. F., Turco M. C., Venuta S. Triggering of CD40 antigen inhibits fludarabine- induced apoptosis in B chronic lymphocytic leukemia cells. Blood 1998; 92: 990 – 5
17. Voorzanger-Rousselot N., Favrot M., Blay J. Y. Resistance to cytotoxic chemotherapy induced by CD40 ligand in lymphoma cells. Blood 1998; 92: 3381 – 7
18. Walker A., Taylor S. T., Hickman J. A., Dive C. Germinal center derived signals act with bcl-2 to decrease apoptosis and increase clonogenicity of drug treated human B lymphoma cells. Cancer Res 1997; 57: 1939 – 46
19. Younes A., Snell V., Consoli U., Clodi K., Zhao S., Palmer J. L., Thomas E. K., Armitage R. J., Andreeff M. Elevated levels of biologically active soluble CD40 ligand in the serum of patients with chronic lymphocytic leukemia. Br J Haematol 1998; 100: 135 – 41
20. Trentin L., Zambello R., Sancetta R., Facco M., Cerutti A., Perin A., Siviero M., Basso U., Bortolin M., Adami F., Agostini C., Semenzato G. B lymphocytes from patients with chronic lymphoproliferative disorders are equipped with different costimulatory molecules. Cancer Res 1997; 57: 4940 – 7
21. Schattner E. J., Mascarenhas J., Reyfman I., Koshy M., Woo C., Friedman S. M., Crow M. K. Chronic lymphocytic leukemia B cells can express CD40 ligand and demonstrate T-cell type costimulatory capacity. Blood 1998; 91: 2689 – 97
22. Vinante E., Rigo A., Tecchio C., Morosato L., Nadali G., Ricetti M. M., Krampera M., Zanolin E., Locatelli F., Gallati H., Chilosi M., Pizzolo G. Serum levels of p55 and p75 soluble TNF receptors in adult acute leukemia at diagnosis: correlation with clinical and biological features and outcome. Br J Haematol 1998; 102: 1025 – 34
23. Barak V., Nisman B., Polliack A. The tumor necrosis factor family and correlation with disease activity and response to treatment in hairy cell leukemia. Eur J Haematol 1999; 62: 71 – 75
24. Beg A. A., Baltimore D. An essential role of NF-B in preventing TNF-α- induced cell death. Science 1996; 274: 782 – 4
25. Liu Z-G., Hsu H., Goeddel D. V., Garin M. Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF-B activation prevents cell death. Cell 1996; 87: 565 – 71
26. Van Antwerp D. J., Martin S. J., Kafri T., Green D. R., Verma I. M. Suppression of TNF-α- induced apoptosis by NF-B. Science 1996; 274: 787 – 9
27. Wang C-Y., Mayo M. W., Baldwin A. S. TNF-and cancer therapy-induced apoptosis: potentiation by inhibition of NF-B. Science 1996; 274: 784 – 7
28. Wu M., Lee H., Bellas R. E., Schauer S. L., Arsura M., Katz D., Fitz Gerald M. J., Rothstein Y. L., Sherr D. H., Sonenshein G. E. Inhibition of NF-B/Rel induces apoptosis of murine B cells. EMBO J. 1996; 15: 4682 – 7
29. Van Antwerp D. J., Martin S. J., Verma I. M., Green D. R. Inhibition of TNF- induced apoptosis by NF-B. Trends Cell Biol 1998; 8: 107 – 11
30. Bauerle P. A., Baltimore D. NF-B: ten years after. Cell 1996; 87: 13 – 6
31. Baldwin A. S., Jr. The NF-B and IB proteins: new discoveries and insights. Annu Rev Immunol 1996; 14: 649 – 83
32. Ghosh S., May M. J., Kopp E. B. NF-B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol 1998; 16: 225 – 60
33. Zong W. X., Bash J., Gelinas C. Rel blocks both anti-Fas- and TNFα-induced apoptosis and an intact Rel transactivation domain is essential for this effect. Cell Death Differ 1998; 5: 963 – 72
34. Wang C. Y., Cusack J. C., Jr., Liu R., Baldwin A. S., Jr. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-B. Nat Med 1999; 5: 412 – 7
35. Chu Z. L., McKinsey T. A., Liu L., Gentry J. J., Malim M. H., Ballard D. W. Suppression of tumor necrosis factor- induced cell death by inhibitor of apoptosis c-IAP2 is under NF-B control. Proc Natl Acad Sci USA 1997; 94: 10057 – 62
36. Wang C. Y., Mayo M. W., Korneluk R. G., Goeddel D. V., Baldwin A. S., Jr. NF-B antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and C-IAP2 to suppress caspase-8 activation. Science 1998; 281: 1680 – 3
37. Wu M. X., Ao Z., Prasad K. V.S., Wu R., Schlossman S. F. IEX-1L, an apoposis inhibitor involved in NF-B- mediated cell survival. Science 1998; 281: 998 – 1001
38. Grumont R. J., Rourke I. J., Gerondakis S. Rel-dependent induction of A1 transcription is required to protect B cells from antigen receptor ligation- induced apoptosis. Genes Dev 1999; 13: 400 – 11
39. Zong W. X., Edelstein L. C., Chen C., Bash J., Gelinas C. The prosurvival Bcl-2 homolog Bfl-l/A1 is a direct transcriptional target of NF-B that blocks TNFα-induced apoptosis. Genes Dev 1999; 13: 382 – 7
40. Opipari A. W., Jr., Hu H. M., Yabkowitz R., Dixit V. M. The A20 zinc finger protein protects cells from tumor necrosis factor cytotoxicity. J Biol Chem 1992; 267: 12424 – 9
41. Dimmeler S., Haendeler J., Sause A., Zeiher A. M. Nitric oxide inhibits APO-1/Fas- mediated cell death. Cell Growth Differ 1998; 9: 415 – 9
42. Berberich I., Shu G. L., Clark E. A. Cross- linking CD40 on B cells rapidly activates NF-B. J Immunol 1994; 153: 4357 – 66
43. Rothe M., Sarma V., Dixit V. M., Goeddel D. V. TRAF2- mediated activation of NF-B by TNF receptor 2 and CD40. Science 1995; 269: 1424 – 7
44. Sutherland C. L., Krebs D. L., Gold M. R. An 11-amino acid sequence in the cytoplasmic domain of CD40 is sufficient for activation of c-Jun N- terminal Kinase, activation of MAPKAP kinase-2, phosphorylation of IBα, and protection of WEHI-231 cells from anti-IgM- induced growth arrest. J Immunol 1999; 162: 4720 – 30
45. Chen C. C., Rosenbloom C. L., Anderson D. C., Manning A. M. Selective inhibition of E-selectin, vascular cell adhesion molecule-1, and intercellular adhesion molecule-1 expression by inhibitors of IBα phosphorylation. J Immunol 1995; 155: 3538 – 45
46. Morishita R., Sugimoto T., Aoki M., Kida I., Tomita N., Moriguchi A., Maeda K., Sawa Y., Kaneda Y., Higaki J., Ogihara T. In vivo transfection of cis element “decoy” against NF-B binding site prevents myocardial infarction. Nat Med 1997; 3: 894 – 9
47. Khaled A. R., Butfiloski E. J., Sobel E. S., Schiffenbauer J. Use of phosphorothioate- modified oligodeoxynucleotides to inhibit NF-B expression and lymphocyte function. Clin Immunol Immunopathol 1998; 86: 170 – 9
48. Bishop M. R., Iversen P. L., Bayever E., Sharp J. G., Greiner T. C., Copple B. L., Ruddon R., Zon G., Spinolo J., Arneson M., Armitage J. O., Kessinger A. Phase I trial of an antisense oligonucleotide OL(1)p53 in hematologic malignancies. J Clin Oncol 1996; 14: 1320 – 6
49. Webb A., Cunningham D., Cotter F., Clarke P. A., di Stefano F., Ross P., Corbo M., Dziewanowska Z. BCL-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet 1997; 349: 1137 – 41
50. Chen F., Castranova V., Shi X., Demers L. M. New insights into the role of NF-B, a ubiquitous transcription factor in the initiation of diseases. Clin Chem 1999; 45: 7 – 17
51. Waddick K. G., Uckun F. M. Innovative treatment programs against cancer: II. NF-B as a molecular target. Biochem Pharmacol 1999; 57: 9 – 17
52. Bentires-Alj M., Hellin A. C., Ameyar M., Chouaib S., Merville M. P., Bours V. Stable inhibition of NF-B in cancer cells does not increase sensitivity to cytotoxic drugs. Cancer Res 1999; 59: 811 – 5
53. Lin Z. P., Boiler Y. C., Amer S. M., Russell R. L., Pacelli K. A., Patiemo S. R., Kennedy K. A. Prevention of brefeldin A- induced resistance to teniposide by the proteasome inhibitor MG-132: involvement of NF-B activation in drug resistance. Cancer Res 1998; 58: 3059 – 65